Insulin cap for Medicare patients signals hope for others
By 2026, the agency will gain the power to start negotiating costs for pharmaceuticals and its beneficiaries' out-of-pocket prescription costs will be limited to $2,000.
By 2026, the agency will gain the power to start negotiating costs for pharmaceuticals and its beneficiaries' out-of-pocket prescription costs will be limited to $2,000.